Artelo Biosciences

ARTL

Biotechnology · Healthcare

Price

$1.12

-0.03 (-2.61%)

Market Cap

$2.6M

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+278.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 622K (2021) → 2.4M (2025)

Artelo Biosciences is a small drug development company focused on medicines that target the body's endocannabinoid system — the network of receptors that helps regulate pain, mood, and appetite. The company is working on experimental treatments for conditions like cancer-related anorexia and other serious diseases. It does not yet sell any approved products and is in the early clinical stage of development.

Artelo makes no revenue today. It funds its research through stock offerings and other financing, which is common for early-stage biotech companies. The company is based in the United States and operates at a significant loss, as reflected in its deeply negative returns. The biggest risk it faces is the uncertainty of clinical trials — most experimental drugs fail before reaching approval — combined with the ongoing need to raise cash to keep research going, which can dilute existing shareholders over time.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

<−1,000% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$5M/ year

↓ Declining (-10% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

6.9%ownership

Insiders own a meaningful stake in the company

Cash Runway

~2 years

$10M cash & investments

$10M cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-36.7%

Weak — -36.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.10

Conservative — low debt load (0.10)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial